Summary
Cencora, Inc. (COR) reported strong revenue growth of 9.3% for fiscal year 2025, reaching $321.3 billion, driven by its U.S. Healthcare Solutions segment. This growth was significantly boosted by increased sales of specialty products and a substantial $7.7 billion in sales for GLP-1 class diabetes and weight loss medications. The company also saw a healthy increase in gross profit of 15.8%, primarily attributed to the U.S. segment's performance, including the recent acquisition of RCA, and higher gains from antitrust litigation settlements. Despite overall positive financial trends, Cencora recorded a significant goodwill impairment of $723.9 million related to its PharmaLex reporting unit, impacting operating expenses. The company's debt also increased significantly due to financing activities for the RCA acquisition, leading to a substantial rise in interest expenses. Looking ahead, Cencora continues to focus on optimizing its U.S. and international healthcare solutions, exploring strategic acquisitions, and managing its diversified business segments.
Financial Highlights
56 data points| Revenue | $321.33B |
| Cost of Revenue | $309.85B |
| Gross Profit | $11.48B |
| SG&A Expenses | $6.49B |
| Operating Expenses | $6.99B |
| Operating Income | $2.63B |
| Net Income | $1.55B |
| EPS (Basic) | $8.02 |
| EPS (Diluted) | $7.96 |
| Shares Outstanding (Basic) | 193.82M |
| Shares Outstanding (Diluted) | 195.21M |
Key Highlights
- 1Revenue increased by 9.3% to $321.3 billion in fiscal year 2025, with the U.S. Healthcare Solutions segment driving growth.
- 2Sales of GLP-1 class diabetes and weight loss products reached $7.7 billion, representing a 26.9% increase.
- 3Gross profit rose by 15.8% to $11.5 billion, benefiting from increased sales and antitrust litigation settlements.
- 4The company completed the acquisition of Retina Consultants of America (RCA) for approximately $5.7 billion, expanding its specialty pharmaceutical offerings.
- 5Operating expenses increased by 14.4%, largely due to acquisition costs, goodwill impairment, and integration expenses.
- 6Total debt increased significantly, reflecting borrowings for the RCA acquisition, leading to a 85.7% increase in net interest expense.
- 7Cencora announced a 9% increase in its quarterly dividend to $0.60 per share, signaling confidence in its financial performance.